HOME >> MEDICINE >> NEWS
Low-Tech Devices, Home Adaptations Preserve Independence, Reduce Health-Care Costs For Physically Frail Elderly

by community agencies for the elderly, such as Meals on Wheels, and help with shopping, household chores and personal care.

All participants were contacted by phone once a month to collect information on new problems or services received, and in the treatment group, to find out if they needed new or different assistive devices or home modifications. Participants also received an in-home assessment every six months to determine their functional status, health and costs of care.

Findings showed that individuals in the treatment group had received an average of 14 devices from the study, or a total of 681. The control group averaged about two additional devices per person from usual service providers, for a total of 80. Assistive devices provided by the study were very low-tech for the most part, involving primarily bath benches, meal-preparation aids, canes, walkers and a variety of devices to help with fine-motor skills.

The treatment group received a total of 69 home modifications, while the control group received a total of eight, the findings showed. Most environmental interventions cost less than $500. The most frequent modifications were addition of handrails, lowering shelves and making storage more accessible.

Assessment of the participants' functional change at the end of the 18-month study showed that while all participants lost some ability to function, the control group declined more than the treatment group in all categories, and had spent four times more on health care. Mann said the functional differences appeared to be directly related to the interventions.

"For example, the control group showed significant decline in the FIM walking item, from 5.43 to 4.77, while treatment group participants who received ambulation equipment and instruction did not show a significant decline. Similarly, the dressing item on the FIM instrument indicated there was no significant decline for the tre
'"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-2626
University at Buffalo
13-May-1999


Page: 1 2 3

Related medicine news :

1. Low-Tech Treatment Proves A Life-Saver In Research Breakthrough
2. Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein
3. Reduced risk of institutionalisation in patients with dementia
4. Reduced exposure tobacco products lessen carcinogen exposure, but medicinal nicotine better
5. Reduced scarring helps nerves grow through spinal injuries
6. Reduced risk for developing type 2 diabetes recommended for inclusion in Xenicals European label
7. Reduced breastfeeding in western countries makes major contribution to incidence of breast cancer
8. Kidney Transplants From Living Donors Reduce Long-Term Costs Of Care
9. Diet Can Reduce Risk Of Cardiovascular Disease
10. UCSF Study Shows That An Herbal Therapy Reduces PSA Levels By Half In Men With Advanced Prostate Cancer
11. Relaxation And Music Significantly Reduce Patients Postoperative Pain

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: